| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/11/2011 | EP2319584A1 Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium |
| 05/11/2011 | EP2319583A1 Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium |
| 05/11/2011 | EP2319582A1 Pharmaceutical products and compositions comprising formoterol, budesonide and tiotropium or oxitropium |
| 05/11/2011 | EP2319581A1 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| 05/11/2011 | EP2319574A2 Drug delivery system for conscious sedation |
| 05/11/2011 | EP2319540A1 Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/11/2011 | EP2319539A1 Prophylactic or therapeutic agent for axial myopia |
| 05/11/2011 | EP2319538A2 Combinations combrising antimuscarinic agents and corticosteroids |
| 05/11/2011 | EP2319537A1 Stabilizer for lymph vessel |
| 05/11/2011 | EP2319536A1 Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
| 05/11/2011 | EP2319533A1 Immunity-inducing agent and method for detection of cancer |
| 05/11/2011 | EP2319532A1 Recombinant dengue virus containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 3, or 4 |
| 05/11/2011 | EP2319527A2 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/11/2011 | EP2319519A1 Composition for inhibiting expression of target gene |
| 05/11/2011 | EP2319518A1 Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 05/11/2011 | EP2319517A1 Use of prodrugs for ocular intravitreous administration |
| 05/11/2011 | EP2319516A1 Compounds for treating inflammatory and autoimmune disorders |
| 05/11/2011 | EP2319515A1 Coccidicide combination for veterinary use |
| 05/11/2011 | EP2319514A1 Stable aqueous solution composition containing sulfonamide compound |
| 05/11/2011 | EP2319513A1 Nicotinic acid compositons for treating hyperlipidemia and related methods therefor |
| 05/11/2011 | EP2319512A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. |
| 05/11/2011 | EP2319511A2 Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| 05/11/2011 | EP2319510A1 Benzoyl peroxide composition for treating skin |
| 05/11/2011 | EP2319509A1 Method of Inhibiting remnant lipoprotein production |
| 05/11/2011 | EP2319508A1 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 05/11/2011 | EP2319507A1 Therapeutic methods employing nitric oxide precursors |
| 05/11/2011 | EP2319506A1 Compositions for intratumoral administration |
| 05/11/2011 | EP2319505A1 Transdermal dosage form comprising an active agent component and an adverse agent component in a ratio from 1:10 up to 10:1 |
| 05/11/2011 | EP2319502A1 Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol |
| 05/11/2011 | EP2319501A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| 05/11/2011 | EP2319498A1 Taste-masked multiparticulate pharmaceutical composition comprising a drug-containing core particle and a solvent-coacervated membrane |
| 05/11/2011 | EP2319497A1 Stable shaped particles of crystalline organic compounds |
| 05/11/2011 | EP2319496A1 Pharmaceutical preparation containing oxycodone and naloxone |
| 05/11/2011 | EP2319494A1 Pharmaceutical compositions for the treatment of asthma |
| 05/11/2011 | EP2319493A2 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 05/11/2011 | EP2318528A1 Rnai constructs and uses therof |
| 05/11/2011 | EP2318427A1 Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology |
| 05/11/2011 | EP2318425A2 Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
| 05/11/2011 | EP2318424A2 Methods for treating multiple sclerosis using antisense oligonucleotides |
| 05/11/2011 | EP2318422A2 Hydrophobically enhanced aminoglycosides |
| 05/11/2011 | EP2318416A1 Spiroaminodihydrothiazine derivatives |
| 05/11/2011 | EP2318415A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 05/11/2011 | EP2318414A2 Imidazo [1,2-a] pyrimidine derivatives, process for their preparation, use as medicaments, pharmaceutical compositions and use as met inhibitors |
| 05/11/2011 | EP2318413A1 Pyrrolobenzodiazepines |
| 05/11/2011 | EP2318412A1 Protein kinase inhibitors |
| 05/11/2011 | EP2318411A2 Crystalline salts of sitagliptin |
| 05/11/2011 | EP2318410A2 New small-molecule pde-10 inhibitors |
| 05/11/2011 | EP2318408A2 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 05/11/2011 | EP2318407A1 Pyrazolopyridine kinase inhibitors |
| 05/11/2011 | EP2318406A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| 05/11/2011 | EP2318404A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| 05/11/2011 | EP2318403A1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| 05/11/2011 | EP2318402A2 Pyrrolidinyl-alkyl-amide derivatives their preparation and their therapeutic application as ccr3 receptor ligands |
| 05/11/2011 | EP2318401A2 Azaindole inhibitors of iap |
| 05/11/2011 | EP2318400A1 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists |
| 05/11/2011 | EP2318399A1 Piperidinyl gpcr agonists |
| 05/11/2011 | EP2318397A2 Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| 05/11/2011 | EP2318396A1 A crystalline form of posaconazole |
| 05/11/2011 | EP2318395A2 Inhibitors of iap |
| 05/11/2011 | EP2318394A1 Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
| 05/11/2011 | EP2318393A1 Novel polymorphs of sunitinib and processes for their preparation |
| 05/11/2011 | EP2318392A2 Pyrimidine derivatives as kinase inhibitors |
| 05/11/2011 | EP2318391A1 Tricyclic heterocycle derivatives as histamine h3 antagonists |
| 05/11/2011 | EP2318390A1 Pyrrole compounds |
| 05/11/2011 | EP2318389A1 Pyridazine derivatives as smo inhibitors |
| 05/11/2011 | EP2318387A1 Bicyclic heterocycle derivatives as histamine h3 receptor antagonists |
| 05/11/2011 | EP2318382A1 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 05/11/2011 | EP2318380A2 Methods of Preparing Imidazole-Based Bicyclic Compounds |
| 05/11/2011 | EP2318378A2 Quinazoline derivatives |
| 05/11/2011 | EP2318376A1 Bi-1h-benzimidazoles as hepatitis c virus inhibitors |
| 05/11/2011 | EP2318375A1 Imidazole carboxamides |
| 05/11/2011 | EP2318372A1 Large substituent, non-phenolic amine opioids |
| 05/11/2011 | EP2318371A2 Novel solid state forms of laquinimod and its sodium salt |
| 05/11/2011 | EP2318370A1 Fluorinated heteroaryls |
| 05/11/2011 | EP2318369A1 Squaric acid derivatives as inhibitors of the nicotinamide |
| 05/11/2011 | EP2318368A1 1-(4-ureidobenzoyl)piperazine derivatives |
| 05/11/2011 | EP2318367A1 Piperidine and pyrrolidine compounds |
| 05/11/2011 | EP2318366A2 Psma-binding agents and uses thereof |
| 05/11/2011 | EP2318365A2 Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof |
| 05/11/2011 | EP2318364A2 Preparation of 3-pyrrole substituted 2-indolinone derivatives |
| 05/11/2011 | EP2318363A1 Heterocyclic derivatives as iap binding compounds |
| 05/11/2011 | EP2318362A2 3-(phenoxyphenylmethyl)pyrrolidine compounds |
| 05/11/2011 | EP2318361A1 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
| 05/11/2011 | EP2318355A1 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use |
| 05/11/2011 | EP2318354A1 Process for the preparation of o-desmethylvenlafaxine |
| 05/11/2011 | EP2318352A2 Cyclohexenyl modulators of chemokine receptor activity |
| 05/11/2011 | EP2318350A1 ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 muM TO ABOUT 10 muM |
| 05/11/2011 | EP2318027A2 Isolation of cyclopamine |
| 05/11/2011 | EP2318026A2 Composition for controlling increase in blood glucose |
| 05/11/2011 | EP2318024A2 Active substance combinations consisting of an anis fruit extract and hyaluronic acid |
| 05/11/2011 | EP2318018A2 Polysaccharides extract from dendrobium for treating allergic diseases |
| 05/11/2011 | EP2318017A1 Regulation of integrin surface expression |
| 05/11/2011 | EP2318016A1 A micro-rna that promotes vascular integrity and uses thereof |
| 05/11/2011 | EP2318015A1 Treatment of cancers of the blood using selected glycomimetic compounds |
| 05/11/2011 | EP2318014A1 New composition for treating autoimmune disorders |
| 05/11/2011 | EP2318013A1 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
| 05/11/2011 | EP2318012A2 Methods and compositions for treating and preventing autoimmune diseases |
| 05/11/2011 | EP2318011A2 Methods and materials for the treatment of acne |
| 05/11/2011 | EP2318010A2 Treating various disorders using trkb agonists |
| 05/11/2011 | EP2318009A1 9-alpha estratriene derivatives as er-beta selective ligands for the prevention and treatment of intestinal cancer |